{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-26-000017","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2026-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.813274+00:00","generated_at":"2026-05-15T06:48:04.718337+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Zentalis selects 400mg QD 5:2 azenosertib monotherapy as pivotal dose for Cyclin E1-positive ovarian cancer","bullets":["Pre-specified interim analysis from DENALI Part 2a showed clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles.","New DENALI Part 2c cohort to include ~40 patients previously treated with taxane-containing regimen for PROC, enrollment expected Q2 2026.","Company expects to complete enrollment in all DENALI Part 2 cohorts and provide topline readout by year-end 2026.","Azenosertib therapeutic profile supports advancement into confirmatory ASPENOVA Phase 3 trial and pre-commercial activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-26-000017","json":"https://secwatch.observer/filing/0001725160-26-000017.json","markdown":"https://secwatch.observer/filing/0001725160-26-000017.md","text":"https://secwatch.observer/filing/0001725160-26-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000017/0001725160-26-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000017/zntl-20260409.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T06:48:04.718337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}